End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
4.26 NZD | +2.65% | -2.74% | -27.80% |
Apr. 22 | New Zealand Shares Jumps on Business Optimism; Ryman Healthcare CEO Resigns | MT |
Apr. 21 | Ryman Healthcare Group CEO Resigns | MT |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- The equity is one of the most attractive in the market with regard to earnings multiple-based valuation.
- The company's share price in relation to its net book value makes it look relatively cheap.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- One of the major weak points of the company is its financial situation.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-27.80% | 1.74B | B | ||
-14.58% | 85.02B | B- | ||
+15.05% | 82.37B | C+ | ||
+10.49% | 29.29B | C+ | ||
-10.17% | 17.21B | B | ||
-1.39% | 16.7B | A- | ||
-31.40% | 11.8B | - | - | |
+1.82% | 12.15B | A- | ||
+31.86% | 12.12B | B- | ||
-0.47% | 12.13B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- RYM Stock
- Ratings Ryman Healthcare Limited